CTOs on the Move

Neuronetics

www.neurostar.com

 
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn`t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Alexandra Williamson
 Associate Vice President of Quality Assurance Profile

Funding

Neuronetics raised $34M on 04/27/2015
Neuronetics raised $80.6M on 02/02/2021

Similar Companies

Oncura

Oncura is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wells Johnson Co.

Wells Johnson Co. is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rusch Anesthesiology

Rusch Anesthesiology is a Research Triangle Park, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bodypoint

Bodypoint is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.